Loading…
← CockpitCompetitor Analysis › RXRX Recursion Pharmaceuticals, Inc. Class AOpen in the cockpit ↗

Recursion Pharmaceuticals, Inc. Class ARXRXCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Uses AI and automated biology experiments to discover and develop new drugs across multiple disease areas.

Momentum weak 30
Mkt cap
$1.76B
US dollars, full cap
Free float
90%
of shares outstanding
$/day
$79.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-102.8 pp
WACC 10.6%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$2.83
1D+3.9%
1W-21.3%
1M-22.8%
3M-15.4%
6M-4.6%
YTD-30.9%
1Y-31.4%
ATR %11.9%
Beta2.86
52w lowhigh46.1% off high

What Recursion Pharmaceuticals does

Uses AI and automated biology experiments to discover and develop new drugs across multiple disease areas.

Pays for research mainly from investor capital and from partners such as Roche and Sanofi, who make upfront and milestone payments tied to drug programs reaching defined stages; no product is on sale. It combined with Exscientia in 2024 to add chemistry design to its biology data.

Products and services

  • Internal drug pipeline (oncology, rare disease)
  • Recursion OS platform (partnered discovery)

Customers

  • Pharma partners including Roche/Genentech and Baye

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • AI-driven drug discovery platform

What could go right

  • Partnership milestone payments
  • AI drug discovery platform validation

What could go wrong

  • High cash burn
  • Unproven AI-to-approved-drug conversion rate

Moat: narrow (data, IP / patents, process know-how). Massive proprietary biological/chemical dataset from automated wet-lab experiments feeds AI models.

Headquarters: Salt Lake City, Utah, US · Founded: 2013 · Employees: 600

Named competitors

Recursion Pharmaceuticals at a glance

Size Recursion Pharmaceuticals (RXRX) is a United States Health Care company (Biotechnology) with a market value of $1.76B, the 1859th largest of 3,085 United States companies the cockpit tracks. Shares closed at $2.83 on 18 Nov 2026.

Performance Over six months the shares fell 4.6%, against -2.7% for the median peer and -2.2% for the United States market (cap-weighted) — 9th lowest of 20 in its peer set.

Growth Revenue grew 56.2% over the last twelve months (peer median +10.8%); the operating margin is -725.4% (peer median -8.7%).

Valuation It trades at 18.8× enterprise value to sales against a peer median of 11.7× (5th most expensive of 16).

Capital Return on invested capital runs 102.8 points below its cost of capital (10.6% WACC).

Short interest Short interest is 22.8% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026Peer median 103RXRX 91
Six months, rebased to 100: Recursion Pharmaceuticals against the median of its 20 peers (local-currency closes).

Recursion Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$68.2M$74.7M$58.8M$44.6M$39.8M
Revenue growth—+27%+32%+12%—
Gross profit-$27.3M-$46.3M-$4.59M-$6.51M-$8.81M
EBITDA-$421M-$564M-$443M-$318M-$226M
Net income-$476M-$645M-$464M-$328M-$239M
Free cash flow-$312M-$378M-$373M-$300M-$121M
Capital expenditure$3.95M$8.63M$17.0M$12.6M$37.4M
Total debt$74.7M$78.0M$108M$50.7M$51.0M

Quarterly statements and history in the cockpit →

Recursion Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%STOK688046ZBIOCOAG145020VERA300601TRAXREPL600226ALVO6882226949MRVIRXRX6-month return →1-month return →
Up and to the right = strong over both horizons. Recursion Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%+300%0×500×1,000×1,500×STOK688046ZBIO145020SEPNBCRX6002266885206949RXRXRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Recursion Pharmaceuticals is the large dot.

Recursion Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (RXRX vs SDGR vs RLAY vs 2228.HK)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Recursion Pharmaceuticals RXRX$1.76B-5%+56%-725%18.8×n/a
Schrodinger SDGR$2.04B+127%+5%-50%6.6×n/a
Relay Therapeutics RLAY$3.65B+27%+24%-3,095%273.1×n/a
XtalPi 2228.HK$2.87B-34%+4%-127%21.3×n/a
Absci ABSI$1.41B+65%-47%-9,155%835.7×n/a

How Recursion Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Recursion Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureRXRXPeer medianRank in peer set
1-month return-22.8%-1.1%2nd lowest of 20
6-month return-4.6%-2.7%9th lowest of 20
Distance from 52-week high-46.1%-33.4%4th lowest of 21
Revenue growth (TTM)+56.2%+10.8%4th highest of 16
Operating margin-725.4%-8.7%5th lowest of 17
EV / Sales18.8×11.7×5th most expensive of 16
ROIC minus cost of capital-102.8 pp-4.4 pplowest of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Recursion Pharmaceuticals RXRXUnited States$1.76B-5%+56%-725%18.8×n/an/a
Stoke Therapeutics STOKUnited States$1.75B-12%-86%-913%50.6×n/an/a
GemPharmatech 688046.SSChina$1.78B+39%+25%22%11.7×33.0%+24.8%
Zenas BioPharma ZBIOUnited States$1.79B+35%-27%-2,748%146.1×n/an/a
Lycia Therapeutics LYCAUnited States$1.81Bn/a-55%-593%n/an/an/a
Hemab Therapeutics COAGUnited States$1.83B+48%n/an/an/an/an/a
Hugel 145020.KSSouth Korea$1.69B-30%+17%38%3.6×-12.1%+15.0%
Vera Therapeutics VERAUnited States$1.85B-26%n/a-4,160%149.9×n/an/a
Shenzhen Kangtai Biological Products 300601.SZChina$1.86B-20%-9%6%4.9×22.7%+3.4%
First Tracks Biotherapeutics TRAXUnited States$1.87B+175%n/an/an/an/an/a
Septerna SEPNUnited States$1.88B+41%+337%-76%14.7×n/an/a
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%2.4×-11.0%+117.9%
Zhejiang Hengtong 600226.SSChina$1.64B-31%+71%0%4.2×n/an/a
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%13.6×n/an/a
ANI Pharmaceuticals ANIPUnited States$1.62B-13%+26%15%1.7×-7.6%+33.5%
Alvotech ALVOUnited States$1.62B+38%-14%12%6.4×n/an/a
Hitgen 688222.SSChina$1.62B-3%+42%27%14.4×33.2%+16.8%
PELL Bio-Med Technology 6949.TWTaiwan$1.62B+28%+8%-1,463%1,650.2×n/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%10.2×n/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a

Questions

Who are Recursion Pharmaceuticals's main competitors?
Named competitors: Schrodinger (SDGR), Relay Therapeutics (RLAY), Insilico Medicine (private or unlisted), XtalPi (2228.HK), Absci (ABSI). The cockpit's measured peer set (industry) also includes Stoke Therapeutics (STOK), GemPharmatech (688046.SS), Zenas BioPharma (ZBIO), Lycia Therapeutics (LYCA), Hemab Therapeutics (COAG), Hugel (145020.KS).
Is Recursion Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 18.8× against a peer median of 11.7×, 5th most expensive of 16 in its peer set.
How has Recursion Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -4.6% against -2.7% for the median peer; over one year -31.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.